Correction of cardiogenic encephalopathy with a Russian metabolic drug

DOI: https://doi.org/10.29296/25877305-2019-08-07
Download full text PDF
Issue: 
8
Year: 
2019

M. Mozheiko, MD; E. Bushueva; M. Potanina, E. Ryabikhin, Candidate of Medical Sciences Healthy Longevity Medical Center, Yaroslavl Regional Clinical Hospital for War Veterans, Yaroslavl

The metabolic drug levocarnitine has been used in patients with coronary heart disease and chronic heart failure. The results obtained from by the study of its efficacy in the drug correction of cardiogenic encephalopathy are presented.
Keywords: 
cardiology
coronary heart disease
chronic heart failure
cardiogenic encephalopathy
cognitive function
levocarnitine
quality of life

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Vertkin A.L. L-karnitin v meditsinskoj praktike: dokazannye effekty // Nevrologija i revmatologija. – 2012; 1: 83–6 [Vertkin A.L. L-carnitine in medical practice: proven effects // Neurology and rheumatology. – 2012; 1: 83–6 (in Russ.)].
  2. Leont'eva I.V., Suhorukov V.S. Znachenie metabolicheskih narushenij v geneze kardiomiopatij i vozmozhnosti primenenija L-karnitina dlja terapevticheskoj korrektsii // Vestn. pediat. farmakol. i nutritsiol. 2006; 2: 12–4 [Leontyeva I.V., Sukhorukov V.S. The value of metabolic disorders in the genesis of cardiomyopathy and the possibility of using L-carnitine for therapeutic correction // Bulletin of Pediatric Pharmacology and Nutrition. – 2006; 2: 12–4 (in Russ.)].
  3. Yoshihisa A., Watanabe S., Yokokawa T. et al. Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction // ESC Heart Fail. – 2017; 4 (3): 360–4.
  4. Helton E., Darragh R., Francis P. et al. Metabolic aspects of myocardial disease and a role for L-carnitine in the treatment of childhood cardiomyopathy // Pediatrics. – 2001; 105: 1260–70.
  5. Lango R., Smolenski R., Narkiewicz M. et al. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass // Cardiovasc. Res. – 2001; 51: 21–9.
  6. Astashkin E.I., Glezer M.G. Rol' L-karnitina v energeticheskom obmene kardiomiotsitov i lechenii zabolevanij serdechno-sosudistoj sistemy // Kardiologija i serdechno-sosudistaja hirurgija. – 2012; 2: 58–65 [Astashkin E.I., Glezer M.G. The role of L-carnitine in the energy metabolism of cardiomyocytes and the treatment of diseases of the cardiovascular system // Cardiology and cardiovascular surgery. – 2012; 2: 58–65 (in Russ.)].
  7. Semigolovskij N.Ju., Vertsinskij E.K., Azanov B.A. i dr. Polozhitel'nye inotropnye svojstva levokarnitina pri sindrome malogo vybrosa u bol'nyh ostrym infarktom miokarda // Kardiologija i serdechno-sosudistaja hirurgija. – 2013; 3: 43–6 [Semigolovsky N.Yu., Vertsinsky E.K., Azanov B.A., et al. Positive inotropic properties of levocarnitine in low discharge syndrome in patients with acute myocardial infarction // Cardiology and cardiovascular surgery. – 2013; 3: 43–6 (in Russ.)].
  8. Astashkin E.I., Glezer M.G. Vlijanie L-karnitina na oksidativnyj stress pri serdechno-sosudistyh zabolevanijah // Med. sovet. – 2016; 10: 104–10 [Astashkin E.I., Glezer M.G. The effect of L-carnitine on oxidative stress in cardiovascular diseases // Medical Council. – 2016; 10: 104–10 (in Russ.)].
  9. Ferrari R., Merli E., Cicchitelli G. et al. Therapeutic effects of Lcarnitineand propionyl-L-carnitine on cardiovascular diseases: a review // Ann. N. Y. Acad. Sci. – 2004; 1033: 79–91.
  10. Aronov D.M. Realii i perspektivy primenenija L-karnitina v kardiologii // Ros. kardiol. zhurn. – 2013; 5: 73–80 [Aronov D.M. The realities and prospects of the use of L-carnitine in cardiology // Russian Journal of Cardiology. – 2013; 5: 73–80 (in Russ.)].
  11. Pasechnik I.N., Skobelev E.I. Perspektivy metabolicheskoj terapii kriticheskih sostojanij // Doktor.Ru. – 2015; 8–9: 22–7 [Pasechnik I.N., Skobelev E.I. Prospects for metabolic therapy of critical conditions // Doctor.Ru. – 2015; 8–9: 22–7 (in Russ.)].
  12. Sharifi M., Eftekhari M., Ostovan M. et al. Effects of a therapeutic lifestyle change diet and supplementation with Q10 plus L-carnitine on quality of life in patients with myocardial infarction: A randomized clinical trial // J. Cardiovasc. Thorac. Res. – 2017; 9 (1): 21–8.
  13. Song X., Qu H., Yang Z. et al. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials // Biomed. Res. Int. – 2017; 6274854. DOI: 10.1155/2017/6274854.
  14. Katz A. Is the failing heart energy depleted? // Cardiology Clinics. – 1998; 16 (4): 633–44.
  15. Serati A., Motamedi M., Emami S. et al. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms // Cardiology. – 2010; 116 (3): 178–82.
  16. Astashkin E.I., Glezer M.G., Orehova N.S. i dr. Vlijanie L-karnitina na obrazovanie radikalov kisloroda fagotsitami krovi patsientov s postinfarktnym kardiosklerozom // Kardiovask. ter. i profilakt. – 2016; 15 (5): 28–32 [Astashkin E.I., Glezer M.G., Orekhova N.S. et al. Effect of L-carnitine on the formation of oxygen radicals by blood phagocytes in patients with post-infarction cardiosclerosis // Cardiovascular therapy and prevention. – 2016; 15 (5): 28–32 (in Russ.)].
  17. Golovkin V., Zuev A., Privalova M. i dr. Kognitivnye narushenija i kardiorespiratornaja disfunktsija pri distsirkuljatornoj entsefalopatii s kardiotserebral'nym sindromom // Vrach. – 2018; 29 (4): 51–3 [Golovkin V., Zuev A., Privalova M. et al. Cognitive impairment and cardiorespiratory dysfunction in dyscirculatory encephalopathy with cardiocerebral syndrome // Vrach. – 2018; 29 (4): 51–3 (in Russ.)].
  18. Flanagan J., Simmons P., Vehige J. et al. Role of carnitine in disease // Nutrition and Metabolism. – 2010; 7: 30.
  19. Koc A., Ozkan T., Karabay A. et al. Effect of L-carnitine on the synthesis of nitric oxide in RAW 264 7 murine macrophage cell line // Cell Biochemistry and Function. – 2011; 29 (8): 679–85.
  20. Orlandi A., Francesconi A., Ferlosio A. et al. Propionyl-Lcarnitine prevents age-related myocardial remodeling in the rabbit // J. Cardiovasc. Pharmacol. – 2007; 50 (2): 168–75.
  21. Dzugkoev S., Mozhaeva I., Otiev M. et al. Effect of L-carnitine, afobazole and their combination with L-arginine on biochemical and histological indices of endothelial dysfunctions in cobalt intoxication in rats // Patologicheskaia fiziologiia i eksperimental’naia terapiia. – 2015; 59 (2): 70–5.
  22. Veronese N., Stubbs B., Solmi M. et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis // Psychosomatic Medicine. – 2018; 80: 154–9.
  23. Veronese N. et al. Effect of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy: A systematic review and meta-analysis // Eur. Geriatr. Med. – 2017; 8 (2): 117–22.
  24. Troshina A.A. Dezagregantnaja terapija – vtorichnaja profilaktika ishemicheskoj bolezni serdtsa // RMZh. – 2018; 11 (1): 54–8 [Troshina A.A. Disaggregant therapy – secondary prevention of coronary heart disease // RMJ. – 2018; 11 (1): 54–8 (in Russ.)].
  25. Drobotja N.V., Kaltykova V.V., Pirozhenko A.A. Sovremennye vzgljady na patogeneticheski obosnovannuju terapiju HSN: u kardiologov est' povod dlja optimizma // RMZh. – 2017; 20: 1435–9 [Drobota N.V., Kaltykova V.V., Pirozhenko A.A. Modern views on pathogenetically substantiated therapy for heart failure: cardiologists have reason for optimism // RMJ. – 2017; 20: 1435–9 (in Russ.)].
  26. Sizova Zh.M., Shih E.V., Mahova A.A. Primenenie L-karnitina v obschej vrachebnoj praktike // Ter. arh. – 2019; 91 (1): 114–20 [Sizov J.M., Shih E.V., Makhova A.A. The use of L-carnitine in general medical practice // Ther. Arch. – 2019; 91 (1): 114–20 (in Russ.)].